Foghorn Therapeutics | BiotechTV

top of page

Search

Talking chromatin regulation at Foghorn Therapeutics - whose partner Lilly will have preclinical data at AACR highlighting how the lead SMARCA2 program could do in combinations with other therapies

Talking chromatin regulation at Foghorn Therapeutics - whose partner Lilly will have preclinical data at AACR highlighting how the lead SMARCA2 program could do in combinations with other therapies

Talking chromatin regulation at Foghorn Therapeutics - whose partner Lilly will have preclinical data at AACR highlighting how the lead SMARCA2 program could do in combinations with other therapies

CEO Adrian Gottschalk describes chromatin regulation at a high level, and walks us through the Lilly partnership targeting SMARCA2, and...

Apr 25

State of Possible: Cigall Kadoch discusses her pioneering work in chromatin regulation that has led to Foghorn Therapeutics

State of Possible: Cigall Kadoch discusses her pioneering work in chromatin regulation that has led to Foghorn Therapeutics

State of Possible: Cigall Kadoch discusses her pioneering work in chromatin regulation that has led to Foghorn Therapeutics

She describes the science behind chromatin and gene regulation, previews upcoming preclinical data the company will have at AACR for its...

Mar 26

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

Allucent Clinical Research Organization™ is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. We’re a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas.

Learn more about Allucent

bottom of page